Seeking Alpha

Galectin Therapeutics (GALT -3.4%) says it's submitted an Investigational New Drug application...

Galectin Therapeutics (GALT -3.4%) says it's submitted an Investigational New Drug application to the FDA to support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis with advanced fibrosis, or fatty liver disease.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|